Chapter 9 - Valence Mercer Wanted a Family That Could Be Managed
Valence Mercer did not send its chairman.
It sent two people more dangerous.
Elena Cross, senior managing partner, and Paul Renwick, head of life-sciences transactions.
Both polished.
Both courteous.
Both trained to make ruthless questions sound like responsible governance.
They arrived in the afternoon with legal counsel trailing at a respectful distance.
Richard wanted to stay.
Thomas wanted to control the conversation.
Mara allowed both to remain, but only after making one thing clear.
“No one answers for me unless I ask.”
Elena Cross seemed faintly pleased by that.
Good.
She began with sympathy.
Always suspicious.
Then moved to the actual issue.
Valence had been prepared to sign a letter of intent with Hale Biotech because the neuro-regenerative division required large-scale commercialization capital and because Victor presented himself as someone who could deliver clean execution.
Now, with family conflict erupting publicly and Richard Hale reappearing, Valence needed to understand whether the company remained governable.
Mara asked, “Governable by whom?”
Elena did not dodge.
“By people able to make difficult decisions quickly.”
There it was again.
Efficiency.
Control.
“Meaning not me,” Mara said.
Paul Renwick answered, “Meaning any structure vulnerable to internal paralysis.”
That at least was honest.
Mara asked Lydia to summarize NorthBridge’s alternative.
She did.
Staged capital.
Licensing.
Preservation of long-term family participation.
Less immediate liquidity than Valence.
Less personal upside for Victor.
Elena Cross did not attack NorthBridge directly.
She simply noted that staged financing came with milestone risk and slower certainty.
Again:
real point.
Victor’s appeal to investors was not invention.
It was speed.
Then Elena asked the question Mara knew was coming.
“Ms. Hale, given your temporary medical limitations and the extraordinary personal disruption surrounding your family, do you believe you can participate constructively in a strategic process over the next sixty days?”
Mara held still.
That was the corporate version of everything Victor had been saying privately.
She answered carefully.
“Yes.”
“On what basis?”
Richard bristled.
Mara raised one hand slightly to stop him.
“On the basis that my sight is compromised, not my understanding.”
Elena said nothing.
So Mara continued.
“Also on the basis that the man you called stable pressed a pillow over my face yesterday when he thought no one was coming.”
That landed.
Paul Renwick shifted in his chair.
No one from Valence had expected the allegation stated so plainly in person.
Then Elena asked a better question.
“If Victor were removed, who actually runs Hale Biotech?”
Finally.
Something that mattered.
Nathan Sloan, the CFO, could manage short-term operations.
Lydia Mercer could protect the science division.
The board’s new special committee could oversee strategic review.
Thomas Bell could address trust governance temporarily.
And Mara—yes, from a hospital bed if necessary—could participate in major decisions with counsel support until her medical status improved.
Was it ideal?
No.
Was Victor indispensable?
Also no.
That was the real issue.
Valence had not become attracted to Hale Biotech only because of the science.
They liked Victor because he seemed able to deliver the company without emotional resistance.
Mara’s existence complicated that.
Richard’s return complicated it more.
Family made assets harder to move.
Elena Cross eventually stopped pretending otherwise.
“Your stepfather told us you were unwilling to make hard choices.”
Mara almost smiled.
“My stepfather defines hard choices as the ones that pay him.”
Lydia hid a reaction badly.
Good.
Then Elena asked what Mara actually wanted.
Not emotionally.
Strategically.
Mara answered.
She was not opposed to outside capital.
Not even opposed to partnership over the neuro-regenerative division.
She was opposed to a structure that stripped the family trust from future upside while rewarding Victor privately for moving the asset out.
She wanted:
* an open review of Valence, NorthBridge, and any alternative,
* full disclosure of side economics,
* preservation of scientific leadership,
* and governance terms that did not depend on her proving she was physically invulnerable.
Elena listened.
Then said something unexpected.
“If your board structure changes and the side economics disappear, Valence might still be interested.”
Richard turned sharply.
Thomas frowned.
Mara stayed quiet.
Because this mattered.
The deal itself was not poison.
Victor’s version of it was.
Elena continued.
“Investors prefer clean control, but they also prefer credible governance. The current situation is neither.”
That was as close to an admission as Mara would get.
Then after they left, Thomas looked disturbed.
“You may have just revived the deal.”
“Maybe.”
“You want that?”
“I want the truth about what the company needs.”
Richard objected.
“Victor tainted Valence.”
“Victor tainted Victor,” Mara said.
Again the room grew quiet.
Because Richard wanted a simpler enemy.
Mara had already learned she wouldn’t get one.
Then the court order arrived.
Interim suspension of Victor’s unilateral trustee powers, effective immediately pending hearing.
Thomas almost smiled.
Richard actually did.
Mara felt relief for approximately thirty seconds.
Then Emily Foster entered with news from the imaging team.
The retinal specialists wanted to proceed first thing in the morning.
There was a real chance Mara would perceive light when the outer bandages came off.
And suddenly the future no longer depended only on law, boards, and dead fathers.
It also depended on whether darkness would finally lift.
May you like
Valence’s visit proved the deal itself might survive Victor’s downfall, meaning Mara would have to separate the company’s needs from her hatred of the man abusing them. In Part 10, the first bandages would come off—and what Mara saw first would alter the fight in ways no legal filing could.
---
